1Ralain MJ, Glassman RH. Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?[J]. Clin Cancer Res,2007, 13(22 Pt1): 6545-6548.
2Carroll KJ. Biomarkers in drug development: friend or foe? A personal reflection gained working within oncology[J]. Pharm Star,2007, 6(4) : 253-260.
3Shah NP, Skaggs BJ, Branford S, et ai. Sequential ABL kinase inhibitor therapy selects for compound drugresistant BCR ABL mutations with altered oncogenic potency[J].J Clin In vest,2007, 117(9) : 2562-2569.
4Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib[J]. PLoS Med,2005, 2(1):e17.
5Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab[J].J Clin Oncol,2007, 25(22) 3230- 3237.
6Shah NP, Nicoll JM, Bleickardt E, et al. Potent transient m hibition of BCR-ABI. by dasatinib leads to complete eytogenet ic remissions in patients with chronic myeloid leukemia: impli cations for patient management and drug development[J].Blood,2006, 108: 2166.
7Dowsett M, Smith 1E, Ebbs SR, et al. Prognostic value of Ki67 expression after short term presurgical endocrine therapy for primary breast cancer[J].J Natl Cancer Inst, 2007. 99(2) 167-170.
8Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a phase 1 trial for patients with recurrent PTEN-deficient glioblastoma[J]. PLoS Med, 2008, 5 (1): e8.
9Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer[J]. N Engl J Med,2004, 351 (8) : 781-791.
10Shaffer DR, Leversha MA, Danila DC, et al. Circulating tumor cell analysis in patients with progressive castrationresis rant prostate cancer[J].Clin Cancer Res,2007, 13(7)2023- 21129.
3Dillon RL,White DE,Muller WJ.The phosphatidylinositol 3-kinase signaling network:implications for human breast cancer[J].Oncogene,2007,26(9):1338-1245.
4Jiang BH,Liu LZ.PI3K/PTEN signaling in tumorigenesis and angiogenesis[J].Biochim BioPhys Acta,2008,1784(1):150-158.
5Meric-Bemstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy[J]. J Clin Oncol, 2009, 27: 2278-2287.
6Dowling RJ, Topisirovic I, Fonseca BD, et al. Dissecting the role of roTOR: Lessons from roTOR inhibitors[J]. Biochim Biophys Acta, 2010, 1804: 433-439.
7Murayama T, Inokuchi M, Takagi Y, et aL. Relation between outcomes and localisation ofpmTOR expression in gastric cancer[J]. Br J Cancer, 2009, 100(5}: 782-788.
